Apr 12, 2022 / 12:00PM GMT
Gil Blum - Needham & Company - Analyst
Good morning and welcome to day two of the annual Needham and Company healthcare conference. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company covering the immune oncology and gene therapy subsectors. It is my pleasure to have with me today Achilles' CEO, Iraj Ali. (Conference Instructions). And with that I will pass it on to Ali.
Iraj Ali - Achilles Therapeutics PLC - CEO
Thanks, Gil. Thanks, Needham, for the invitation and the opportunity to tell you a little bit more about Achilles Therapeutics. I'd ask those, in their own time, to take a look at the forward-looking statement at the top of our presentation and I'll jump into this story.
So, Achilles is developing precision medicines that -- for solid tumors targeting a wide range of cancers using a, what we call, clonal neoantigen reactive T cell or cNeT. But essential to the story is the ability to go after a novel class of target present in all tumor cells and absent from healthy tissue.
We really think this is
Achilles Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers